Instytut Farmakologii Polskiej Akademii Nauk

Centre National De La Recherche Scientifique

Universitè De Montpellier

Uniwersyter Jagiellonski

Uniwersytet Jagiellonski

Grzegorz Satala

Andrzej J Bojarski

Jean Martinez

Gilles Subra

Maciej Pawlowski

Pawel Zajdel

Anna Wesolowska

Adam Hogendorf

Xavier Bantreil

Evelina Colacino

Tomasz Kos

Piotr Popik

Anna Partyka

Katarzyna Grychowska

Tomasz Lenda

Jakub Staron

Ryszard Bugno

Rafal Kurczab

Agata Hogendorf

Wesolowska Anna

The invention relates to a new class of substituted indole derivatives that are able to activate 5-HTserotonin receptor. These compounds bind 5-HTserotonin receptor with high affinity and selectivity, while possessing favourable physicochemical properties. The compounds of the invention are the first described low-basicity 5-HTreceptor agonists. The invention also relates to use of such compounds in the treatment or prevention of 5-HTreceptor-related disorders, especially of the central nervous system. The invention also relates to the isotopically labelled compounds for use in the in vivo diagnostics or imaging of a 5-HTserotonin receptor.

Imidazolyl-substituted indole derivatives binding 5-HT7 serotonin receptor and pharmaceutical compositions thereof

This invention concerns pyrroloquinoline derivatives as antagonists of 5-HT6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in schizophrenia, anxiety, depression, maniac depression, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, panic attacks, attention deficit hyperactivity disorder, attention deficit disorder, Parkinson's disease, Huntington's disease, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, obesity and type-2 diabetes, functional bowel disorder, Irritable Bowel Syndrome. The compounds have the general formula (XIV), wherein the symbols have the meanings given in the description.

[object Object]

Growing community of inventors

Kraków, Poland

Grzegorz Satala